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Objective: The true prevalence of Mycoplasma pneumoniae infections involving the respiratory
tracts of HIV-infected individuals is still unclear. This study examined the prevalence of M.
pneumoniae in 100 HIV-infected individuals at an AIDS care center in Chennai, India, using
conventional laboratory techniques and interpretation criteria.
Methods: Diagnosis was based on culture, cold agglutination test, and commercial enzyme-linked
immunosorbent assay (ELISA) for the qualitative determination of IgM antibodies against M.
pneumoniae. The efficacies of the different diagnostic procedures used in the studywere analyzed.
Results: The prevalence of M. pneumoniae was 31% by culture and 21% by IgM ELISA. Cough
(p = 0.03, OR 3.8, 95% CI 1—17.8), myalgia (p = 0.04, OR 2.5, 95% CI 1—6.6), rales (p = 0.04, OR
2.4, 95% CI 1—6.6), and cervical adenopathy (p = 0.03, OR 2.7, 95% CI 1—7.1) were the symptoms
that significantly corroborated culture positivity. Patients positive forM. pneumoniae by culture or
IgM antibody had significantly greater CD4+ T-cell depletion and anemia than those without any
evidence of infection.
Conclusions: This study provides the means to diagnoseM. pneumoniae infection and information
on the prevalence of the pathogen in HIV-infected individuals in resource constrained settings.
Although modern molecular techniques may provide more insight into the prevalence of
M. pneumoniae in HIV-infected individuals, conventional methods can still be used in diagnosis.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +91 22 24925317; fax: +91 44 24927609.
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Mycoplasma pneumoniae is recognizedas an important patho-
gen in the human respiratory tract, where it can persist for
monthsafter an initial infection in theabsenceofameasurable
immune response. It has recentlybeenassociatedwithexacer-
bation of chronic conditions including bronchial asthma and
atypical cold agglutinin pneumonia.1—3 M. pneumoniae infec-
tion occurs endemically and occasionally epidemically in all
age groups.1,4 Bronchopneumonia develops in 3—10% of
infected persons, accounting for 20% or more of community-
acquired pneumonias (CAP) overall.
Gnarpe et al. detectedM. pneumoniae in 13.5% of healthy
individuals.5 While Lockman et al. reported a 17% association
of M. pneumoniae with lower respiratory disease in Bots-
wana, Park et al. reported a 7% prevalence in HIV-infected
adults6,7 suggesting that M. pneumoniae is common among
HIV-infected adults.M. pneumoniae is also a significant cause
of severe pneumonia requiring hospitalization in elderly
patients, often resulting in death.8
Current diagnostic methods primarily rely on serology, as
symptoms vary a lot. Culture is time-consuming, although it is
the gold standard for diagnosis.9 IgM ELISA has been reported
to be the most sensitive and specific test for diagnosis of M.
pneumoniae infections10—13 and specific IgM antibody detec-
tion allows the diagnosis of acute or recent infection using a
single serum sample.14—16
Very few reports are available globally on the prevalence
of M. pneumoniae in HIV-infected patients,6,7 and data on M.
pneumoniae in HIV-infected individuals along the Indian
subcontinent is entirely lacking.17 Therefore, a study was
designed to determine the prevalence of M. pneumoniae in
HIV-infected patients with pulmonary complaints at a ter-




This study was conducted between August 2004 and July
2005, after prior approval from the Institutional Review
Board (IRB) of the YRG-Center for AIDS Research and Educa-
tion, University of Madras. Written, informed consent was
obtained from all the patients, or their legal representatives,
before study enrolment. The study was carried out in com-
pliance with good clinical practice, including the Interna-
tional Conference on Harmonization Guidelines and the
Declaration of Helsinki.
Patients
A total of 100 inpatients aged 18 years were eligible for
inclusion. HIV infection was confirmed in the patients using
Western blot assay (positive for HIV-1 antibody) (Immunetics,
Inc., MA, USA) against gp160 env, gp120 env, p66 pol, p55 gag,
gp41 env, p24 gag, and p17 gag. All patients with acute X-ray-
verified upper and lower pulmonary complaints were
enrolled. The body temperature, pulse rate, blood pressure,
and pulse oximetry were recorded from all the patients upon
admission. Patients with evidence of nosocomial pneumonia,lung cancer, and those terminally ill were excluded from the
study. HIV-infected patients for the present study were
classified based on the absolute CD4+ lymphocyte counts
(Guava Technologies, CA, USA) and other indicator conditions
suggestive of AIDS as per the CDC, 1993.18
Respiratory and blood specimens
Sputum specimens were obtained according to a standard
protocol by respiratory therapists. Briefly, the subjects were
hydrated orally prior to induction. Patients inhaled nebu-
lized 3% saline for 20 min from a DeVilbiss Ultra-Neb 99
ultrasonic nebulizer in a closed system via a mouthpiece.
Respiratory specimens were collected in sterile containers
and a single blood specimen (3 mL) was collected aseptically
from all the patients. The sera were separated and stored at
20 8C until tested for analysis. The criteria for diagnosis of
M. pneumoniae infection were a positive culture or a posi-
tive IgM ELISA.
Bedside cold agglutination test (BCAT)
Bedside cold agglutination tests were carried out as pre-
viously described by Griffin.19 Briefly, 1 mL of the patient’s
blood collected in a BD vacutainer1 (BD, Franklin Lakes, NJ,
USA) with anticoagulant, was incubated in an ice pack, and
after several minutes, the red blood cells could be seen to
agglutinate on the sides of the tube. When warmed in the
hand and examined, dissociation of the hemagglutination
could be observed in the tube.
Cold agglutination test (CAT)
Cold agglutinin (CA) titration was performed as earlier
described by Griffin.19 A positive agglutination titer of 32
was taken as suggestive of recent or current M. pneumoniae
infection. A positive CA titer together with a positive IgM
ELISA supports the diagnosis of a current M. pneumoniae
infection.
Culture
The respiratory specimens were cultured on classical Hay-
flick’s diphasic medium with 0.001% methylene blue (Hime-
dia, Mumbai, India) and agar plates incubated at 37 8C in a
Gas-pak container (BBL Inc., ML USA) for up to three
weeks. Preliminary biological identification was carried
out using the hemadsorption test.20 Briefly the positive
plates were flooded with a suspension of 0.5% guinea pig
erythrocytes and incubated at 37 8C for 30 min before
washing with phosphate-buffered saline (PBS), pH 7.2.
The plates were then observed under 10  magnification.
The isolates were later confirmed by growth inhibition
tests using high titer sera against M. pneumoniae.21 Fol-
lowing identification, the organism was stored at 70 8C
for future analysis.
Mycoplasma pneumoniae qualitative IgM-ELISA
Specimens were tested using a commercial qualitative
ELISA (IBL-GmbH, Hamburg, Germany) according to the
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cut-off index, which is equal to the absorbance of the
patient’s serum sample at 450 nm divided by twice the
absorbance of the negative control at 450 nm. A cut-off
index of >12 U/mL was considered as positive and a value
<8 U/mL was considered negative. Values between 8 and
12 U/mL were considered borderline.
Other investigations
Immunological (CD4+ count and CD4%) and hematological
parameters (total leukocyte count (TC), total lymphocyte
count (TLC), total platelet count (TPC), erythrocyte sedi-
mentation rate (ESR), and hemoglobin of the HIV-infected
patients were analyzed.
Statistical analysis
The prevalence of M. pneumoniae is presented as a per-
centage with the 95% confidence interval (95% CI). The
association between the symptoms and signs, clinical com-
plaints, and culture positivity were analyzed using Pear-
son’s Chi-square test and odds ratio (OR) with 95% CI. The
relationship between M. pneumoniae by culture positivity
and anemia in the HIV-infected patients screened were
analyzed using Student’s t-test and the difference in mean
values using Fisher’s 95% CI. Sensitivity, specificity, correct
classification rate (concurrent value), misclassification
rate, positive predictive value, negative predictive value,
false positivity and false negativity rates, likelihood ratio
positive test, likelihood ratio negative test, Cohen’s kappa
(k), and McNemar’s test were calculated to compare dif-
ferent diagnostic tests with respect to sputum, the gold
standard for diagnosis of Mycoplasma infections in
limited resource settings. A p value 0.05 was considered
significant.Table 1 Clinical status of patients with an etiologic diagnosis of
Symptoms and signs Mycoplasma pneumoniae culture
Positive
(N = 31) n (%)
Negative
(N = 69) n (
Anemia 19 (61.3) 46 (66.7)
Smoking 17 (54.8) 36 (52.2)
Cough 28 (90.3) 49 (71.0)
Malaise 22 (71.0) 41 (59.4)
Headache 16 (51.6) 30 (43.5)
Chills 8 (25.8) 13 (18.8)
Sore throat 7 (22.6) 13 (18.8)
Chest discomfort 17 (54.8) 34 (49.3)
Nasal symptoms 4 (12.9) 5 (7.2)
Myalgia 20 (64.5) 29 (42.0)
Skin lesions 5 (16.1) 9 (13.0)
Fever 26 (83.9) 48 (69.6)
Rales 18 (58.1) 25 (36.2)
Pharyngeal erythema 7 (22.6) 13 (18.8)
Cervical adenopathy 15 (48.4) 18 (26.1)
Crepitations 13 (41.9) 23 (33.3)
a Test of significance was Pearson’s Chi-square test. NS, not significaResults
A total of 100 HIV-infected patients were screened in the
present study. The age range of the HIV-infected patients
was 18—60 years and the mean age was 40 years. The age
mean  SD of themale and female HIV-infected patients were
37.29 7.87 years (range 19—60 years) and 35.7  7.63 years
(range25—53years), respectively. Themean values of TCwere
6.05  109/L, TLC 0.94  109/L, ESR 78.3 mm, hemoglobin
9.71 g/dL, and TPC was 242.6  109/L. Definitive diagnosis
ofM. pneumoniae was made in 31 (31%) HIV-infected patients
by culture and 21 (21%) by IgM ELISA. Cold agglutinins were
detected in 34 (34%) HIV-infected patients. All patients posi-
tive for CA titers were concurrently positive for BCAT.
The clinical status of patients with an etiologic diagnosis
of respiratory complaints due to M. pneumoniae is presented
in Table 1.
Among the various methods used for the detection of M.
pneumoniae infection, culture (sputum and throat swab
combined) has been compared with other methods as it
has been reported to be the gold standard. The diagnostic
profile ofM. pneumoniae infection in HIV-infected individuals
is shown in Table 2. A definitive diagnosis was made in 31
cases as per the criteria for diagnosis while a non-specific
diagnosis was made in an additional three patients.
Compared to culture, the sensitivity of CATwas 96.5% and
specificity 94.2% and there was no significant difference in
the hematological and immunological parameters among the
patients who were positive by culture. Nevertheless, a sig-
nificant depletion (t = 2.01, p = 0.05) in the levels of absolute
CD4+ counts was evident among patients who were positive
by IgM ELISA (75  69.1 cells/mL) compared to those who
were negative (119  135.2 cells/mL). Subjects who were
culture positive for M. pneumoniae had significantly lower
hemoglobin levels (8.8  1.7 g/dL, OR 2.4, t = 3.05, 95% CI
0.79—4.01, p = 0.01) than culture negative subjectspulmonary complaints due to Mycoplasma pneumoniae











4.33 0.04 2.5 (1—6.6)
— NS —
— NS —
4.16 0.04 2.4 (1—6.6)
— NS —
4.81 0.03 2.7 (1—7.1)
— NS —
nt ( p  0.05 considered significant).
Mycoplasma pneumoniae in HIV-infected patients 235
Table 3 Association of HIV status withMycoplasma pneumoniae infection in HIV-infected patients screened forM. pneumoniae by
culture (sputum and throat swab) and IgM ELISA
HIV statusa Culture IgM ELISA
Positive (N = 31) Negative (N = 69) Positive (N = 21) Negative (N = 79)
A1 0 1 0 1
A2 1 4 0 5
A3 5 15 5 15
B2 2 2 2 2
B3 4 7 1 10
C1 2 0 1 1
C2 1 4 1 4
C3 16 36 11 41
a Classified based on CDC criteria, 1993.18
Table 2 Diagnosis of Mycoplasma pneumoniae in HIV-infected patientsa
No. Age (years) Culture Serology
Induced sputum Throat swab BCAT CA titer IgM ELISA
1 40 + + + 32 +
2 37 + + + 64 +
3 35 + + + 32 +
4 30 + + + 32 +
5 28 +  + 32 
6 28 +  + 32 +
7 37 +  + 32 
8 24 +  + 32 
9 45  + + 32 
10 35 + + + 32 +
11 37 +  + 32 
12 30 +  + 32 
13 42 + + + 32 +
14 47  + + 32 
15 59 + + + 32 +
16 33 +  + 64 
17 60 + + + 32 
18 31 + + + 64 +
19 31  + + 32 +
20 33 + + + 32 +
21 29  + + 32 +
22 33 +  + 64 +
23 38 + + + 64 +
24 60 + + + 32 +
25 41 + + + 32 +
26 35 + + + 64 +
27 35 + + + 32 +
28 36 + + + 64 +
29 32 + + + 32 +
30 40 + + + 32 +
31 35   + 32 
32 45 +  + 32 
33 34   + 32 
34 35   + 32 
a The criteria for diagnosis were a positive culture or a positive IgM ELISA irrespective of a diagnostic CA titer (CAT is a non-specific test for
M. pneumoniae infections). Accordingly 31 patients were found tomeet the criteria. All the patients positive by CAT (cold agglutination test)
were concurrently positive by BCAT (bedside cold agglutination test).
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pneumoniae infection in HIV-infected patients screened by
culture and IgM ELISA is shown in Table 3.
Discussion
Our study has shown that M. pneumoniae is prevalent among
HIV-infected patients, viz., 31% by culture (induced sputum
and throat swab combined) and 21% by IgM ELISA. Recent
studies have demonstrated that HIV-infected adults may
never reveal measurable IgG againstM. pneumoniae.22 Occa-
sionally, patients continue to produce detectable levels of
IgM due to incomplete clearance of the organisms from the
respiratory tract.22,23 Furthermore, immunocompromised
patients such as those with HIV infection might not mount
a detectable antibody response. Culture and serology are still
the standard laboratory methods for the diagnosis of M.
pneumoniae infections,16,24 and therefore both methods
have been used in our resource-limited setting. The comple-
ment fixation test (CFT) is reported to give false positive
results24—27 and so was not considered. Park et al. documen-
ted a 7% prevalence of M. pneumoniae in HIV-infected indi-
viduals using immunofluorescence methods, while Lockman
et al. reported a 17% prevalence.6,7 Our study has shown that
culture (combined) was found to be 100% sensitive and 87%
specific compared to IgM ELISA (95% CI 84—100). Diagnostic
titers of cold agglutinins were evident among 34% of cases by
CAT, the conventionally used serological test for diagnosing
M. pneumoniae infections. Cold agglutinins are the first non-
specific indicators of acute M. pneumoniae infection whose
association has been described in 34—86% of M. pneumoniae
infections.19 Moreover, since cold agglutinins are not found
usually in normal individuals, their detection aids in M.
pneumoniae diagnosis. In addition, the interpretation of a
negative result is critical because a negative result does not
exclude infection.19 Our study showed that CA titer was
96.8% sensitive and 94.2% specific compared to culture,
albeit being a non-specific test, and could be used as an
adjunct to other expensive procedures in resource-limited
settings. However, more studies are required to substantiate
our findings.
Although rapid methods for the detection of mycoplasmas
are developing, the choice of the best specimen and thorough
sampling are essential for optimal performance.24 M. pneu-
moniae frequently causes lower respiratory tract infections
(LRT) and specimens obtained from the LRT may be more
sensitive than throat swabs. Some authors have shown that
induced sputum is an important sampling technique for the
assessment of lower airway secretions.28 Throat swabs may
be used in preference to other respiratory specimens in M.
pneumoniae infection, as patients do not normally produce
sufficient sputum. However, our previous pilot study data
supported induced sputum as the best specimen.17 The pre-
sent study reports that among the two culture methods
employed, sputum culture was found to be more sensitive
(90%) while throat swab was more specific (94.9%) compared
to IgM ELISA. Therefore, sputum samples could be more
sensitive for rapid detection of M. pneumoniae in clinical
specimens. Throat swab culture has 81.8% positive predictive
value compared to 70% by sputum culture. If culture were not
used as a diagnostic test, diagnosis would not have been
established in 10 cases, as ELISA proved only 20 cases positivefor IgM against M. pneumoniae. Culture has been shown to
give a false positivity rate of 13% (95% CI 6—22) and a false
negativity rate of 0% (95% CI 0—16), the likelihood ratio of a
positive test being 7.90 (4.4—14.1). However, CAT should
never be compared for diagnostic usage to culture, as the
former is only 50% specific.19 Therefore, comparison was
made as the test was used in the study.
Clyde found that Mycoplasma was responsible for approxi-
mately 30% of cases of community-acquired pneumonia in the
general population, and that the role of M. pneumoniae in
adults with HIV infection needs to be defined.11 Studies in
other geographical areas have shown different prevalence
rates in HIV-infected adults and our report differs substan-
tially from others; Lockman et al. reported 17% from Bots-
wana and Park et al. a 7% prevalence from Seattle, USA.6,7 We
have reported earlier that mycoplasmas are more frequent in
the sputum of HIV-infected patients (36%) than from that of
HIV-uninfected individuals (16.6%).29 Teel et al., reported
that M. pneumoniae may be more common in HIV-infected
than HIV-negative patients.30 Studies by some authors have
shown that Mycoplasma spp colonize 12.5% of HIV-infected
cases compared to <0.9% HIV-negative patients,31 whilst
others have documented Mycoplasma spp in 87% of HIV-
positive patients compared to only 20% from HIV-negative
controls.32
Detection of M. pneumoniae specific IgM by commercial
ELISA does not correlate with culture (and CA values) in the
present analysis, as 10 cases positive by culture have failed to
demonstrate IgM against M. pneumoniae. This could be
attributed to compromised antibody responses in AIDS
patients.22 M. pneumoniae might continuously be liberated
in respiratory secretions with no detectable antibody
response, and therefore measurements of antibody levels
are of limited value and diagnosis cannot be based on the
demonstration of specific IgM alone as reported by others,33—
37 hence culture was attempted. In addition, since adult
patients in particular are known to develop weak IgM
responses during primary infection or reinfection15,37,38 it
was important to examine the diagnostic yields of testing
using culture and CA assay. Therefore, we chose culture along
with direct ELISA instead of a capture immunoassay described
by others39 to avoid false-negative IgM reactions caused by
IgG antibodies occupying the epitopes of the solid-phase
antigens.40
Foy et al. reported several clinical parameters that posi-
tively or negatively correlated with M. pneumoniae infec-
tion.41 Our study has shown that cough (OR 3.8, 95% CI 1—
17.8, p = 0.03), myalgia (OR 2.5, 95% CI 1—6.6, p = 0.04),
rales (OR 2.4, 95% CI 1—6.4, p = 0.04), and cervical adeno-
pathy (OR 2.7, 95% CI 1—7.1, p = 0.03) were found to corro-
borateM. pneumoniae culture positivity. However, in general
it is difficult to discriminate M. pneumoniae from other
pathogens causing respiratory tract infection on clinical
parameters only, and this emphasizes the need for laboratory
confirmation.
Our data suggest there may be an association between
AIDS stage and M. pneumoniae infection (Table 3) but this
warrants a larger sample size.
An association between cold agglutinins and anemia dur-
ing M. pneumoniae infection was also evident in our study
and is in agreement with reports by others.42 Among the 31
culture positive cases, 19 cases (8.8  1.7 g/dL) showed a
Mycoplasma pneumoniae in HIV-infected patients 237significant depletion in HgB levels (t = 3.05, p = 0.01, OR 2.4,
95% CI 0.79—4.01) compared to those without anemia
(11.2  2.7 g/dL). The finding corroborated the reports that
M. pneumoniae infection may lead to hemolytic anemia that
is related to cold agglutination.41
Interestingly, our study has disclosed a 34% diagnostic CA
titer with 96.8% sensitivity and 94.2% specificity compared to
culture, suggesting that CA titer could still be used in limited
resource settings and third-world nations for prompt diag-
nosis.43 Comparison has been made between culture and CAT
because the latter was positive in all the cases that were
positive by specific tests viz. culture. However, while using
CAT, false positivity cannot be ruled out, the probable reason
being cold agglutinins are also produced during other under-
lying conditions such as pregnancy, staphylococcemia, try-
panosomiasis, Raynaud’s disease, etc. Moreover, Khoo et al.
reported that HIV-infected adults may carry M. pneumoniae
for months after illness44 and therefore, detection does not
necessarily indicate infection but rather may reflect respira-
tory carriage. Studies by Beersma et al. have shown that
serology may be non-specific.45
In conclusion, culture has a low positive predictive value
and should therefore be used in conjunction with CAT in
resource-limited settings in particular as the test has
more sensitivity and specificity in HIV-infected patients.
Sputum culture was found to be more sensitive (90%)
while throat swab was more specific (94.9%) compared
to IgM ELISA.
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